Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors

    SAN FRANCISCO, Aug. 21 /EMWNews/ -- Medizone

International, Inc. (Pink Sheets: MZEI) announces the appointment of

Michael E. Shannon, M.A., M.Sc., M.D. to its Board of Directors. Dr.

Shannon received his medical degree from Queen's University in Canada,

which included advanced training in surgery and sports medicine. He also

holds post-graduate degrees in neurochemistry and physiology. He has been

actively engaged in applied medical research within these areas for over 27

years. He served in the Canadian Forces for 31 years retiring at the rank

of Commodore (Brigadier General equivalent) as Deputy Surgeon General for

Canada. During the first Gulf War, Dr. Shannon served as the senior medical

liaison officer for all of the Canadian forces. In 1996 he assumed

responsibilities within Health Canada for re-organizing the Canadian blood

system. Working with both the provincial and federal governments, he

oversaw the development of a new corporate entity dedicated exclusively to

the management of blood services in Canada. He was then appointed Director

General for the Laboratory Centre for Disease Control, a position he held

for three years. In December 2000, Dr. Shannon left the Canadian federal

government to pursue a new career in industry. In that capacity he

simultaneously directed a phase III clinical trial in Canada, the United

States and Great Britain for an artificial blood substitute product.

Following completion of that work he was asked to accept a special

assignment with the Canadian Federal Government Auditor General's office.

His assignment was to conduct a cost benefit analysis of all government

sponsored pharmacare programs and make recommendations directly to the

Parliament of Canada. His assignment and presentation to Parliament on that

project was completed in November 2004. Dr. Shannon recently worked on a

special project assignment as Senior Medical Advisor to the Canadian Public

Health Agency. His assignment was to review and help rebuild the Canadian

Public Health Agency's Emergency Medical Response Capacity. His work in

that regard with the Canadian government was completed the end of July this

year.



    Internationally respected for his expertise, Dr. Shannon has been

actively engaged in medical bio-oxidative (O3 based), research since 1987

and was directly responsible for the first human clinical trial to have

ever been approved in North America which examined the efficacy of O3

delivered via autohemotherapy in the treatment of AIDS. He was also

responsible for several primate studies utilizing O3 involving scientists

from various departments within the Canadian Federal Government, as well as

senior investigators from Medizone International and Cornell University.



    Medizone's Chairman and CEO, Edwin Marshall commented; "On behalf of

the members of the board and all of the Company's shareholders, we welcome

Dr. Shannon to our Board of Directors. The wisdom and expertise Dr. Shannon

brings to Medizone is unparalleled in the history of our company. I

consider him a remarkable man and feel honored to be able to refer to him

as a professional associate. This appointment signals an immense step

forward in the reorganization of Medizone International.



    Medizone International, Inc., is a research and development stage

company engaged in the development of patented and unpatented technologies

and protocols for O3 based bio-oxidative treatment of diseases caused by

lipid enveloped viruses, including Acquired Immune Deficiency Syndrome

(AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood

products and veterinarian serum products, and the treatment of external

pathogenic conditions.



    This Press Release contains certain forward looking statements that

involve substantial risks and uncertainties, including, but not limited to,

the results of ongoing clinical studies, economic conditions, product and

technology development, production efficiencies, product demand,

competitive products, competitive environment, successful testing and

government regulatory issues. Additional risks are identified in the

company's filings made with the Securities and Exchange Commission.